

MEDICATION GUIDE
MYQORZO (my-kor-zo)
(aficamten)
tablets, for oral use

What is the most important information I should know about MYQORZO?

MYQORZO can cause serious side effects, including:

- **Heart failure**, a condition where the heart cannot pump with enough force. Heart failure is a serious condition that can lead to death. You must have echocardiograms before and during treatment with MYQORZO and monitor for signs and symptoms of heart failure. People who develop a serious illness such as a serious infection or who develop a new or worsening irregular heartbeat have a greater risk of heart failure during treatment with MYQORZO.
Tell your healthcare provider or get medical help right away if you develop new or worsening:
 - shortness of breath
 - swelling in your legs
 - a racing sensation in your heart (palpitations)
 - fatigue
 - chest pain
 - rapid weight gain
- **The risk of heart failure is also increased when MYQORZO is taken with certain other medicines.** Tell your healthcare provider about the medicines you take, both prescribed and obtained over-the-counter, before and during your treatment with MYQORZO.
- **Because of the risk of heart failure, MYQORZO is only available through a restricted distribution program called the MYQORZO Risk Evaluation and Mitigation Strategy (REMS) Program.**
 - Your healthcare provider must be enrolled in the MYQORZO REMS Program for you to be prescribed MYQORZO.
 - Before you start treatment with MYQORZO, you must enroll in the MYQORZO REMS Program. Talk to your healthcare provider about how to enroll in the program. You will be given information about the program when you enroll.
 - Before you take MYQORZO, your healthcare provider and pharmacist will make sure you understand how to take MYQORZO safely, which will include returning for echocardiograms when advised by your healthcare provider. MYQORZO can only be dispensed by a certified pharmacy that participates in the MYQORZO REMS Program. Your healthcare provider can give you information on how to find a certified pharmacy.
 - If you have any questions about the MYQORZO REMS Program, ask your healthcare provider, go to www.MYQORZOREMS.com, or call 1-844-285-7367.
- See “**What are the possible side effects of MYQORZO?**” for information about side effects.

What is MYQORZO?

MYQORZO is a prescription medicine used to treat adults with symptomatic obstructive cardiomyopathy (oHCM) to improve functional capacity and symptoms.

It is not known if MYQORZO is safe and effective in children.

Who should not take MYQORZO?

Do not take MYQORZO if you take a medicine called rifampin.

Before taking MYQORZO, tell your healthcare provider about all of your medical conditions, including if you:

- are pregnant or plan to become pregnant. It is not known if MYQORZO can cause harm to your unborn baby. Tell your healthcare provider if you become pregnant during treatment or within 3 weeks after the last dose of MYQORZO. There is a pregnancy safety study for MYQORZO. Your healthcare provider should report your pregnancy exposure to Cytokinetics, Inc.
- are breastfeeding or plan to breastfeed. It is not known if MYQORZO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with MYQORZO.

Before and during MYQORZO treatment, tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking MYQORZO with certain medicines may lead to increased levels of MYQORZO in your blood and increase your risk of heart failure. **Do not stop or change the dose of a medicine or start a new medicine without telling your healthcare provider.**

Especially tell your healthcare provider if you take the medicines:

- fluconazole (if used for more than 3 days)
- voriconazole
- fluvoxamine

How should I take MYQORZO?

- Take MYQORZO exactly as your healthcare provider tells you to take it.
- Do not change your dose of MYQORZO without talking to your healthcare provider first.
- Take MYQORZO 1 time a day, at about the same time each day,
- Take MYQORZO with or without meals.
- Swallow the MYQORZO tablet whole.
- If you miss a dose of MYQORZO, take it as soon as possible and take your next dose at your regularly scheduled time the next day. Do not take 2 doses on the same day to make up for a missed dose.
- Your healthcare provider may change your dose or temporarily stop your treatment with MYQORZO if you have certain side effects.
- If you take too much MYQORZO, call your healthcare provider or Poison Control Help Line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

What are the possible side effects of MYQORZO?

MYQORZO can cause serious side effects including:

- **Heart failure.** See “What is the most important information I should know about MYQORZO?

The most common side effect of MYQORZO is high blood pressure (hypertension).

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Cytokinetics at 1-833-633-2986.

How should I store MYQORZO?

- Store MYQORZO at room temperature between 68°F to 77°F (20°C to 25°C).
- MYQORZO comes in a bottle with a child-resistant closure.

Keep MYQORZO and all medicines out of the reach of children.

General information about the safe and effective use of MYQORZO.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use MYQORZO for a condition for which it was not prescribed. Do not give MYQORZO to other people, even if they have the same symptoms that you have; it may harm them. You can ask your pharmacist or healthcare provider for information about MYQORZO that is written for health professionals.

What are the ingredients in MYQORZO?

Active ingredients: aficamten

Inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate (non-bovine), mannitol, microcrystalline cellulose, and sodium lauryl sulfate.

The tablet coating contains: carmine, FD&C Blue No. 2, glyceryl mono and dicaprylate, polyvinyl alcohol, polyvinyl alcohol graft polyethylene copolymer, talc and titanium dioxide.

Distributed by: Cytokinetics, Incorporated, South San Francisco, CA 94080

Patent information: <https://cytokinetics.com/patents>

MYQORZO and the MYQORZO logo are trademarks of Cytokinetics in the U.S. CYTOKINETICS® and the C-shaped logo are trademarks of Cytokinetics in the U.S.
© 2025 Cytokinetics, Incorporated, All Rights Reserved.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Issued: 12/2025